Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Inclusion Criteria:

• At least 18 years old and has provided informed consent.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• Pathologically confirmed NSCLC, either locally advanced or metastatic, not amenableto curative surgery or radiotherapy.

• Measurable disease per RECIST v1.1.

• Adequate organ function (bone marrow, liver, kidney, coagulation).

• One to two prior lines of therapy including an anti-PD-1/anti-PD(L)-1 agent andplatinum-based chemotherapy.

• Documented RAS mutation status, defined as Nonsynonymous mutations in KRAS, NRAS, orHRAS at codons 12, 13, or 61 (G12, G13, or Q61).

• Able to take oral medications.

Exclusion Criteria:

• Prior therapy with direct RAS-targeted therapy or docetaxel.

• Untreated central nervous system (CNS) metastases.

• Medically significant comorbidities (significant cardiovascular disease, lungdisease, or impaired GI function).

• Ongoing anticancer therapy.

• Pregnant or breastfeeding.